OBSVのニュース
ObsEva SA Submits Marketing Authorization Application to the European Medicines Agency for YSELTY® (linzagolix) for the Treatment of Women with Uterine Fibroids - Stocks News Feed 2020/11/24 06:00:00 Stocks News Feed
If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options for the management of uterine fibroids: 100 mg once daily for women with a contraindication to or who prefer to avoid hormonal add-back therapy (ABT) 200 mg once daily with concomitant ABT for long-term use (beyond 6 months) 200 mg… Read More »ObsEva SA Submits Marketing Authorization Application to the European Medicines Agency for YSELTY® (linzagolix) for the Treatment of Women with Uterine Fibroids
ObsEva +15% on positive ebopiprant data in preterm labor (NASDAQ:OBSV) 2020/11/16 10:17:02 Seeking Alpha
ObsEva (NASDAQ:OBSV) jumps 15% premarket after announcing positive topline results of PROLONG, the Phase 2a proof-of-concept trial of ebopiprant (OBE002) i
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor - Stocks News Feed 2020/11/16 06:00:00 Stocks News Feed
Over 50% reduction of pre-term delivery within 48hrs of treatment in singleton pregnancy Maternal, fetal and neonatal safety comparable to placebo Data supports advancement of ebopiprant to Phase 2b dose range finding Geneva, Switzerland and Boston, MA – 16 November 2020 – ObsEva SA (NASDAQ:OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel… Read More »ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
ObsEva SA to present at Jefferies Virtual London Healthcare Conference, November 17 – 19, 2020 2020/11/13 06:00:00 GlobeNewswire
Geneva, Switzerland and Boston, MA – November 13, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and…
Life Science executive joins ObsEva as CEO (NASDAQ:OBSV) 2020/11/09 10:39:35 Seeking Alpha
ObsEva SA (NASDAQ:OBSV) has appointed Brian O’Callaghan, to succeed Dr Ernest Loumaye, as Chief Executive Officer and member of the company’s Executive Com
ObsEva appoints Brian O’Callaghan as Chief Executive Officer 2020/11/09 06:00:00 GlobeNewswire
Geneva, Switzerland and Boston, MA – November 9, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and…
ObsEva EPS misses by $0.16 (NASDAQ:OBSV) 2020/11/05 07:37:26 Seeking Alpha
ObsEva (NASDAQ:OBSV): Q3 GAAP EPS of -$0.49 misses by $0.16. Cash and cash equivalents at September 30, 2020 to $50.6M. Press Release
Q3 2020 EPS Estimates for Obseva SA (NASDAQ:OBSV) Increased by Analyst 2020/10/24 01:44:45 The Lincolnian
Obseva SA (NASDAQ:OBSV) – Research analysts at SVB Leerink upped their Q3 2020 earnings per share (EPS) estimates for Obseva in a research report issued on Tuesday, October 20th. SVB Leerink analyst A. Fadia now forecasts that the company will post earnings per share of ($0.37) for the quarter, up from their previous forecast of […]
Q3 2020 EPS Estimates for Obseva SA (NASDAQ:OBSV) Lifted by SVB Leerink 2020/10/22 22:08:43 Daily Political
Obseva SA (NASDAQ:OBSV) – Equities researchers at SVB Leerink upped their Q3 2020 earnings per share (EPS) estimates for Obseva in a note issued to investors on Tuesday, October 20th. SVB Leerink analyst A. Fadia now forecasts that the company will post earnings of ($0.37) per share for the quarter, up from their previous estimate […]
ObsEva SA Presented Two Late-Breaking Posters at the ASRM 2020 Virtual Scientific Congress October 17-21 2020/10/22 01:00:00 Benzinga
Geneva, Switzerland and Boston, MA – October 22, 2020 – ObsEva SA (NASDAQ:OBSV), a clinical-stage biopharmaceutical company developing and commercializing …
ObsEva down 42% on late-stage linzagolix data (NASDAQ:OBSV) 2020/07/06 15:29:21 Seeking Alpha
ObsEva SA (OBSV -41.8%) slumps on more than a 7x surge in volume on the heels of results from two Phase 3 clinical trials evaluating lead candidate linzago
Livongo Health and Trevena among healthcare gainers; ObsEva among losers 2020/07/06 15:03:36 Seeking Alpha
Gainers: Trinity Biotech (NASDAQ:TRIB) +13%. Zynex (NASDAQ:ZYXI) +13%. Livongo Health (NASDAQ:LVGO) +12%. Trevena (NASDAQ:TRVN) +11%. Mesoblast MESO +11%.
The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In Focus 2020/07/06 12:08:57 Benzinga
Biotech stocks rebounded in the holiday-shortened week ending July 2 as investors reacted to pending clinical trial readouts and the news flow surrounding COVID-19 vaccine and treatment development. Australian biopharma Alterity Therapeutics Ltd (NASDAQ: ATHE ) was among the biggest gainers of the week after the company said it received FDA guidance for the Phase 2 study for its Parkinsonian disorder drug. Inovio Pharmaceuticals Inc (NASDAQ: INO ) and Pfizer Inc. (NYSE: PFE )/ BioNTech SE – ADR (NASDAQ: BNTX ) were among the companies that issued updates on their coronavirus vaccine programs. The week also saw FDA issuing guidance on the approval of COVID-19 vaccines, with the agency suggesting a vaccine needs to demonstrate at least 50% efficacy in a placebo-controlled trial. The following are key catalysts for the unfolding … Full story available on Benzinga.com
ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids 2020/07/06 05:00:00 GlobeNewswire
PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24 PRIMROSE 2…